[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342289-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342289-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pharmaceutical-companys-choices-of-indication-for-the-first-clinical-projects-in-oncological-drug-development-in-the-united-states","Pharmaceutical Company’s Choices of Indication for the First Clinical Projects in Oncological Drug Development in the United States","","Analyzes how lead indication, defined as cancer type, is selected for the first clinical development projects of new oncological drugs in the United States, and how pharmaceutical company type relates to that choice. Uses 576 new US projects since 2000, characterized via multiple correspondence analysis by cancer morbidity (market size), prior company experience, and risk attitude. Mega firms favor higher-morbidity, previously experienced cancers and low-to-moderate risk, while diverse small firms cover both major and rare cancers and a mix of risk levels. Common trends show past developed and launched cancers are more likely, whereas high five-year survival and high competition cancers are less likely, suggesting entry where companies can leverage experience and strengths while balancing efficiency and unmet needs.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pharmaceutical-companys-choices-of-indication-for-the-first-clinical-projects-in-oncological-drug-development-in-the-united-states/342289/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pharmaceutical-companys-choices-of-indication-for-the-first-clinical-projects-in-oncological-drug-development-in-the-united-states/342289.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the study analyze about new oncological drugs in the US?","Question",{"text":63,"@type":64},"It analyzes factors shaping the choice of the lead indication (cancer type) in the first clinical development projects, and how company type is associated with that choice.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the 576 projects selected and characterized?",{"text":68,"@type":64},"The study selected 576 new clinical development projects in the US since 2000 and characterized them using multiple correspondence analysis based on cancer morbidity, prior experience with the cancer type, and attitudes toward development risks.",{"name":70,"@type":61,"acceptedAnswer":71},"What common tendencies were found across all companies regarding lead indication?",{"text":72,"@type":64},"Cancer types the company had previously developed and launched were more likely to be chosen, while cancer types with high five-year survival rates and high competition were less likely to be chosen.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342289,1791233428,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Therapeutic Innovation & Regulatory Science (2025) 59:9–19 [https://doi.org/10.1007/s43441-024-00718-2](https://doi.org/10.1007/s43441-024-00718-2)  \nANALYSIS  \nPharmaceutical Company’s Choices of Indication for the First Clinical Projects in Oncological Drug Development in the United States  \nCan Wu1 · Shunsuke Ono1  \nReceived: 27 March 2024 / Accepted: 25 October 2024 / Published online: 31 October 2024 © The Author(s) 2024  \nAbstract  \nWe analyzed factors shaping the choice of the lead indication (i.e., cancer type) in the first clinical development projects of new oncological drugs in the United States (US), and how the type of pharmaceutical company is related to this choice. We selected 576 new clinical development projects in the US since 2000 for analysis. These projects were characterized according to three potential perspectives detected by multiple correspondence analysis: the morbidity of the cancer type which corresponds to market size of each cancer type, the company’s previous experience with the cancer type, and the company’s attitude to development risks. Mega firms tend to choose cancer types with higher morbidity (and largemarket), previously experienced cancer types, while diverse small firms choose both major and rare cancers and both high-and low-risk projects, indicating that different sizes of firms utilize different development entry patterns. Common tendencies concerning the choice of lead indication were found across all companies. Cancer types the company had developed and launched in the past were more likely to be chosen; cancer types with high five-year survival rates and those with high competition were less likely to be chosen. The study showed that pharmaceutical companies seem to enter clinical development from cancer types where they can demonstrate their strengths and advantages through experience, depending on each cancer type’s different market sizes and development difficulties. The results could provide clues for considering what support measures and incentives are appropriate to balance the efficiency of industrial development and the fulfillment of society’s unmet medical needs.  \nKeywords Oncological drug development · First developed indication · Lead indication · Cancer type · Company behavior  \nIntroduction  \nOncological drug development is one of the most important area in drug development. Cancer incidence is expected to rise significantly through 2050, and more than 2,000 new oncology clinical trials started in 2023 with novel modalities and significant promise for cancer treatment, including cell and gene therapies, antibody-drug conjugates, multispecific antibodies, and radioligand therapies [1] . Many cancer types share common molecular pathways for tumorgenesis, cell proliferaion and metastasis [2] . So that, in most  \n􀀍 Shunsuke Ono [shun-ono@mol.f.u-tokyo.ac.jp](shun-ono@mol.f.u-tokyo.ac.jp)  \n1 Laboratory of Pharmaceutical Regulatory Science, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan  \ncases, a drug candidate is developed as potentially effective against multiple cancer types. Given the constraints of industrial research and development (R&D) resources and the different probability of development success for each cancer type, the order and timing of obtaining approval for each indication is an important component of lifecycle management (LCM) for pharmaceutical companies [3] .  \nIt is a crucial R&D decision for pharmaceutical companies to target and initiate the clinical development of anew oncological drug, given the science level pertinent to the product, medical needs, regulation, and economic and business prospects. The choice of lead indication is critical for a company’s development strategy. The market for anticancer drugs is fragmented by indication, and competition with rival products occurs in such fragmented markets. New molecular entities are granted marketing exclusivity in the US for f","cbCaijh0J12fUutw","https://ap.wps.com/l/cbCaijh0J12fUutw","pdf",3051535,11,"English","# Analysis\n## Lead indication selection in first clinical projects\n## Study design and project characterization\n## Company size and risk-attitude patterns\n## Cross-company common tendencies\n## Implications for support measures and incentives\n# Introduction\n## Importance of lead indication in lifecycle management\n## Regulatory approval timelines and orphan strategies\n## Drugability and company decision factors\n## Prior research on regulatory schemes and indication extension","[{\"question\":\"What does the study analyze about new oncological drugs in the US?\",\"answer\":\"It analyzes factors shaping the choice of the lead indication (cancer type) in the first clinical development projects, and how company type is associated with that choice.\"},{\"question\":\"How were the 576 projects selected and characterized?\",\"answer\":\"The study selected 576 new clinical development projects in the US since 2000 and characterized them using multiple correspondence analysis based on cancer morbidity, prior experience with the cancer type, and attitudes toward development risks.\"},{\"question\":\"What common tendencies were found across all companies regarding lead indication?\",\"answer\":\"Cancer types the company had previously developed and launched were more likely to be chosen, while cancer types with high five-year survival rates and high competition were less likely to be chosen.\"}]","Pharmaceutical Company’s Choices of Indication for the First Clinical Projects in Oncological Drug Development in the United States | PDF",1790046022,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f343ff2be879854ad03e5ee4b4f8a5e7.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d67a5c2b2afa12be4964b9b8dade34aa.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e34139f78c8209c9baa57f925d2ddfdb.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de4ddafa48035fd0c5a98b6480fa063e.webp",980,1301]